Effect of gimeracil capsules combined with radiotherapy on breast cancer and on tumor markers, human epidermal growth factor receptor-2 and midkine levels

Abstract

Abstract:

AIM: To explore the effect of gimeracil capsules combined with radiotherapy on breast cancer, and on tumor marker, human epidermal growth factor receptor-2 (HER-2) and level of midkine (MK). METHODS: Sixty-four breast cancer patients were selected by random number table method from January 2010 to May 2016 in our hospital, sixty-two cases in each group. The control group was treated with three-dimensional conformal radiotherapy; the study group was treated with three-dimensional conformal radiotherapy and gimeracil capsule; the therapy continued for 2 courses of treatment. Clinical efficacy and adverse reaction incidence rate were compared between two groups; tumor markers (CEA, CA125, CA153) and changes of MK, HER-2 level were analyzed. RESULTS:The effective rate (50%) and tumor control rate (81.25%) of the study group were higher than those of the control group (25%, 53.13%), the difference were statistically significant (P<0.05); Before treatment, no significant difference of CEA, CA125, CA153 was observed between groups (P>0.05), while all the indexes decreased after treatment, and the study group presented more significant change than the control group (P<0.05); Before treatment, no significant difference of HER-2 and MK level was observed between groups (P>0.05), while all the indexes decreased after treatment, and the study group presented more significant change than the control group (P<0.05). Both groups presented no IV degrees of adverse reactions, and compared with control group (31.24%, 37.51%, 34.37%), the incidence of leucopenia, diarrhea, nausea and vomiting (34.38%, 34.38%, 37.51%) of the study group presented no statistically significance (P>0.05). CONCLUSION: Gimeracil capsules combined with radiotherapy exhibited remarkable effect on breast cancer, and on the serum tumor markers, human epidermal growth factor receptor-2 and midkine expression level. With high safety, it is worthy of promotion.

Key words: gimeracil capsules, radiotherapy, breast cancer, tumor marker, human epidermal growth factor receptor-2

CLC Number:

R965.2

YAN Jianqiang,NIE Gaihong. Effect of gimeracil capsules combined with radiotherapy on breast cancer and on tumor markers, human epidermal growth factor receptor-2 and midkine levels[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 899-903.

References

［1］Matzinger O, Heimsoth I, Poortmans P,et al.Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)［J］. Acta Oncol,2010,49(1):24-34.
［2］罗代琴,冉立,常建英,等.辅助放化疗在Ⅰ~Ⅱ期乳腺癌保乳术后的治疗效果［J］.贵阳医学院学报,2015,40(3):288-290.
［3］Kim KH, Noh JM, Kim YB,et al.Does internal mammary node irradiation affect treatment outcome in clinical stage II-III breast cancer patients receiving neoadjuv ant chemotherapy［J］ ? Breast Cancer Res Treat,2015,152(3):589-599.
［4］郑瑛,陈钦,贾苗苗,等.保乳术后放疗对乳腺癌局部淋巴结转移患者预后的影响［J］.中国肿瘤临床,2014,41(21):1394-1398.
［5］张锡贵,李太东,倪武,等.早期乳腺癌保乳手术联合放化疗治疗方案的临床研究［J］.中国现代普通外科进展,2015,18(9):709-711.
［6］陈孝平,汪建平.外科学［M］.8版.北京:人民卫生出版社,2013:256-260.
［7］席娟,郄远巍.新辅助化疗联合乳腺癌改良根治术对乳腺癌组织中分子标志物Survivin、HER-2、p53表达的影响及意义［J］.临床和实验医学杂志,2016,15(12):1183-1186.
［8］李树玲.乳腺肿瘤学［M］.2 版.北京:科学技术文献出版社,2007:978-987．
［9］Chung Y, Kim JW, Shin KH,et al.Dummy run of quality assurance program in a phase 3 randomized trial investigating the role of internal mammary lymph node irradiation in breast cancer patients: Korean Radiation Oncology Group 08-06 study［J］.IInt J Radiat Oncol Biol Phys,2015,91(2):419-426.
［10］张芹,颜淑霞,马杰,等.三维适形放疗联合S-1治疗局部晚期胰腺癌临床观察［J］.现代肿瘤医学,2014,22(1):129-131.
［11］李继恩,王旭东,姜在鹏,等.替吉奥口服联合三维适形放疗治疗三阴性乳腺癌效果观察［J］.山东医药,2016,56(18):45-47.
［12］Yeung R, Conroy L, Long K,et al.Cardiac dose reduction with deep inspiration breath hold for left-sided breast cancer radiotherapy patients with and without regional nodal irradiation［J］. Radiat Oncol, 2015,10(1):200.
［13］Tyran M, Mailleux H, Tallet A,et al.Volumetric-modulated arc therapy for left-sided breast cancer and all regional nodes improves target volumes coverage and reduces treatment time and doses to the heart and left coronary artery, compared with a field-in-field technique［J］. J Radiat Res,2015,56(6):927-937.
［14］郑婷,钱其军.替吉奥治疗晚期乳腺癌的研究进展［J］.药学实践杂志,2015,33(6):557-560.
［15］高彤,王晓燕,赵丽霞,等.食管胃结合部癌治疗中替吉奥胶囊同步三维适形放疗的临床应用［J］.疑难病杂志,2014,13(7):690-693.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[7]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[8]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[9]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[10]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[11]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
[12]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[13]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[14]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[15]	SUN Hong, HOU Jialin, CAI Jiaqin, WEI Xiaoxia, ZHUANG Jie. SUMO E3 ligase mediates androgen receptor transcription to promote tamoxifen resistance of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 285-291.